Skip to content
In recent years, Artificial Intelligence (AI) has boomed in healthcare. AI is helping scientists obtain relevant data, accurately predict diseases at early stages, and […]
I am BIO Podcast: How AI and biotech can ‘run evolution at hyperspeed’ Read More »
On Friday, March 10, 2023, the United States Food and Drug Administration (FDA) approved Acadia Pharmaceuticals’ drug for genetic Rett syndrome, the company announced
FDA approves Acadia’s DAYBUE for the treatment of Rett syndrome Read More »
Although the collapse of Silicon Valley Bank (SVB) is raising concerns among biotech companies and venture capital firms, the United States government has taken
How does the SVB collapse affect biotech companies? Read More »
A broad coalition of 65 national and state agriculture and bioscience organizations, including the Biotechnology Innovation Organization (BIO), expressed their gratitude in a letter
USTR action to address Mexico corn ban strongly supported by ag & bioscience groups Read More »
The 2024 budget proposal President Biden officially released yesterday is facing rocky ground ahead calling for, among other things, more innovation-killing drug price controls
Drug price controls in Biden’s proposed budget hurtful for patients, R&D Read More »
Experts told a House subcommittee Wednesday that China’s government coordinates a strategy to steal U.S. intellectual property – and the waiver of COVID IP would
Congress shines a light on China’s strategy to steal U.S. IP Read More »
On March 6, 2023, the United States Trade Representative (USTR) made a request for technical consultations concerning Mexico’s biotech corn ban under the U.S.-Mexico-Canada
U.S. takes step toward legal resolution of Mexico’s biotech corn ban Read More »
“Strong patents, and an efficient, predictable, and objective patent system, are critical to the seeds industry, which depends on patent-driven activities to fuel the
Strong IP protection for seeds key to enabling biotech innovation Read More »
On March 8, 2023, during the first markup of health care bills this year, the Health Subcommittee of the House Energy and Commerce Committee
Legislation potentially banning QALYs due to discrimination is under review Read More »
The breakthrough Alzheimer’s drug LEQEMBI could receive traditional Food and Drug Administration (FDA) approval later this year after receiving Accelerated Approval in January. Developed
Alzheimer’s drug LEQEMBI granted Priority Review for traditional approval Read More »
